Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ACAD is in the long-term up 880% in 16 years.
Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
|Shares Outstanding||EPS||-2.61||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-85.71%||Sales Growth - Q/Q||-91.67%||P/E||-10.38|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-38.09%||ROE||-40.35%||ROI|
|Current Ratio||18.01||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||-123217%||Net Profit Margin||-122364%||Dividend Payout Ratio|
|Cash From Financing Activities||1.44 M||Cash From Investing Activities||38.47 M||Cash From Operating Activities||-25.35 M||Gross Profit|
|Net Profit||-40.38 M||Operating Profit||-40.55 M||Total Assets||301.96 M||Total Current Assets||299.9 M|
|Total Current Liabilities||16.65 M||Total Debt||Total Liabilities||16.87 M||Total Revenue|
|High 52 week||39.14||Low 52 week||15.12||Last close||17.87||Last change||1.53%|
|RSI||52.92||Average true range||0.66||Beta||1.75||Volume||3.38 M|
|Simple moving average 20 days||0.08%||Simple moving average 50 days||-2.47%||Simple moving average 200 days||-35.73%|
|Performance Week||2.47%||Performance Month||-2.14%||Performance Quart||-30.98%||Performance Half||-40.61%|
|Performance Year||-34.78%||Performance Year-to-date||-40.65%||Volatility daily||1.95%||Volatility weekly||4.36%|
|Volatility monthly||8.94%||Volatility yearly||30.98%||Relative Volume||1230.89%||Average Volume||2.95 M|
|New High||New Low|
2020-06-02 07:27:00 | Is Acadia Pharmaceuticals a Buy?
2020-05-27 12:15:04 | ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
2020-05-08 22:31:17 | Acadia Pharmaceuticals ACAD Q1 2020 Earnings Call Transcript
2020-05-08 16:27:35 | Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT
2020-05-08 10:55:02 | ACADIA's ACAD Q1 Earnings & Revenues Fall Shy of Estimates
2020-05-07 18:10:10 | Acadia Pharmaceuticals ACAD Reports Q1 Loss, Lags Revenue Estimates
2020-05-07 16:06:00 | ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
2020-05-05 16:05:00 | ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
2020-04-30 12:34:04 | Acadia Pharmaceuticals ACAD Expected to Beat Earnings Estimates: Should You Buy?
2020-04-15 16:05:00 | ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
2020-04-13 09:43:23 | We're Not Worried About ACADIA Pharmaceuticals's NASDAQ:ACAD Cash Burn
2020-03-27 11:31:03 | Why Is Acadia ACAD Up 1.1% Since Last Earnings Report?
2020-03-22 22:04:50 | Largest Insider Trades of the Week
2020-03-20 14:11:31 | Hedge Funds Have Never Been This Bullish On ACADIA Pharmaceuticals Inc. ACAD
2020-02-28 20:35:00 | Don’t Expect Virgin Galactic Shares to Keep Rocketing Upward
2020-02-27 11:13:04 | ACADIA ACAD Q4 Earnings Surpass, Nuplazid Drives Sales
2020-02-27 03:10:19 | Edited Transcript of ACAD earnings conference call or presentation 26-Feb-20 10:00pm GMT
2020-02-26 17:35:10 | Acadia Pharmaceuticals ACAD Reports Q4 Loss, Tops Revenue Estimates
2020-02-26 16:05:00 | ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-05 06:13:12 | Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc. NASDAQ:ACAD
2020-01-29 05:00:00 | ACADIA- From Depression to Schizophrenia
2020-01-17 08:45:01 | ACADIA ACAD Up More Than 100% in the Past Year: Here's Why
2020-01-05 17:36:00 | Best Stocks of the Decade: Acadia's Drug Development Success
2019-12-23 11:30:04 | Has ACADIA Pharmaceuticals ACAD Outpaced Other Medical Stocks This Year?
2019-12-19 10:18:03 | Biotech Stock Outlook: M&A Activity Retains Growth Streak
2019-12-17 08:38:01 | 5 Biotech Stocks That Have More Than Doubled This Year
2019-12-11 09:04:02 | 5 Biotech Stocks Up More Than 100% This Year So Far
2019-12-06 05:00:00 | A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know
2019-12-05 23:01:02 | Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. ACAD Before The Q4 Rally
2019-12-05 16:08:46 | Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone
2019-12-05 10:08:00 | Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data